ORMP (oramed.com) Net Profit

Corporate emblem and logo of Oramed Pharmaceuticals (ORMP)

Oramed Pharmaceuticals (ORMP) net balance correlates with revenues from oral protein partnerships. The current trend is supported by the expansion of the POD system through B2B licensing and the reallocation of liquidity into fresh assets for a new growth surge. Profit dynamics reflect a search for equilibrium points, with the indicator holding at 0.18, illustrating the transformation of fundamental achievements into real capital.

ORMP (oramed.com) Company Net Income history from 07/04/2022 to 10/30/2026

Financial and market metric breakdowns for oramed.com (ORMP)

- price and consensus price forecast:
Stock Quotes Oramed Pharmaceuticals Inc.|ORMP - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization ORMP|ORMP - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Oramed Pharmaceuticals|ORMP - Company Book Value|Market-to-Book Ratio oramed.com|ORMP - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Oramed Pharmaceuticals|ORMP - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Oramed Pharmaceuticals Inc.|ORMP - Company Aggregate Debts|Debts to Book Value ORMP|ORMP - Company Long-Term Debt|Company Short-Term Loans and Borrowings Oramed Pharmaceuticals|Immediate Liquidity oramed.com
- net income and valuation multiples indicators:
ORMP - Company Net Income
Fundamental valuation:ORMP Oramed Pharma
Flagship merchandise of Oramed

This metric serves as a critical filter during asset stress testing, allowing speculative noise to be separated from actual business performance. The daily net income calculation captures actual financial results, while the net profit trend for Oramed Pharmaceuticals (ORMP) reflects the impact of regulatory decisions and oral insulin clinical trial outcomes against a backdrop of stable, non-cyclical demand.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Company Net Income|SCPH - Company Net Income|Final Profit TECX (Tectonic Therapeutic, Inc.)|TNXP: Net Profit|China SXT Pharmaceuticals, Inc. (SXTC) - Net Profit|Company Net Income Eupraxia Pharmaceuticals, Inc.|Net Income BioHarvest Sciences, Inc. (BHST)|Net Profit EXOZ|ENTX - Company Net Income|Net Profit HYFT (MindWalk Holdings)|ABVC: Company Profit|CPIX: Net Income|Final Profit QNTM (Quantum BioPharma Ltd.)|FibroGen Corp (FGEN) - Company Net Income|Profit After Tax TELO (Telomir Pharmaceuticals Corp)|RANI (Rani Therapeutics Holdings) - Net Profit|SNYR: Final Profit|Net Profit RLYB|Net Profit lexariabioscience.com (LEXX)|Company Net Income Pulmatrix Corp PULM|Final Profit PTHL|APM - Company Net Income|lyratherapeutics.com (LYRA) - Net Income|IBO: Net Profit|TNF Pharmaceuticals, Inc. (TNFA) - Net Profit|YCBD (cbdMD Inc.) - Net Profit|Net Income PainReform Corp (PRFX)|Net Profit CYTO|LIPO - Company Net Income|OptiNose - Net Income|Net Profit Pieris Pharmaceuticals Inc PIRS|PROC: Net Income|Petros Pharma - Profit After Payment of Taxes|QLI: Net Profit|SLRN - Net Financial Result|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit